PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care
  • Artificial Intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment.
  • Collaboration with PathAI expands pathologist access to innovative AI-powered technology to support companion diagnostic and drug development programs.
  • Builds on Roche’s Digital Pathology Open Environment, expanding the company’s commitment to improving patient outcomes and advancing personalised healthcare through innovation

Basel, 15 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has entered an agreement with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology. Under the development and distribution agreement, the companies will jointly develop an embedded image analysis workflow for pathologists. This workflow will allow PathAI image analysis algorithms to be accessed within NAVIFY Digital Pathology, the cloud version of Roche’s uPath enterprise software. This collaboration is now possible through Roche’s Digital Pathology Open Environment, which allows pathologists to securely access third-party AI-powered technology alongside Roche’s growing menu of AI-based image analysis tools.

This agreement with PathAI is among the first to expand digital tools through the Roche open environment, and is one of the first for PathAI to distribute its AI-powered solutions via a third party platform.

“Working together, Roche and PathAI will bring the latest leading technologies to pathologists through our digital pathology solu…

Read More...
Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care

Articles